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Background: In the clinical practice of neoadjuvant chemotherapy, response markers are very important. We aimed
o investigate whether tumor markers CEA(carcino-embryonic antigen), CA19-9(carbohydrate antigen 19–9), CA72-4
(carbohydrate antigen 72–4), and CA125(carbohydrate antigen 125) can be used to evaluate the response to
neoadjuvant chemotherapy, and to evaluate the diagnosis and prognosis value of four tumor markers in the patients
of gastric cancer.
Methods: A retrospective review was performed of 184 gastric cancer patients who underwent a 5-Fu, leucovorin, and
oxaliplatin (FOLFOX) neoadjuvant chemotherapy regimen, followed by surgical treatment. Blood samples for CEA,
CA19-9, CA72-4, and CA125 levels were taken from patients upon admission to the hospital and after neoadjuvant
chemotherapy. Statistical analysis was performed to identify the clinical value of these tumor markers in predicting
the survival and the response to neoadjuvant chemotherapy.
Results: Median overall survival times of pretreatment CA19-9-positive and CA72-4-positive patients (14.0 +/−2.8 months
and 14.8 +/−4.0 months, respectively) were significantly less than negative patients (32.5 +/−8.9 months and
34.0 +/−10.1 months, respectively) (P = 0.000 and P = 0.002, respectively). Pretreatment status of CA19-9 and CA72-4
were independent prognostic factors in gastric cancer patients (P = 0.029 and P = 0.008, respectively). Pretreatment
CEA >50 ng/ml had a positive prediction value for clinical disease progression after neoadjuvant chemotherapy
according to the ROC curve (AUC: 0.694, 95% CI: 0.517 to 0.871, P = 0.017). The decrease of tumor markers CEA, CA72-4,
and CA125 was significant after neoadjuvant chemotherapy (P = 0.030, P = 0.010, and P = 0.009, respectively), especially
in patients with disease control (including complete, partial clinical response, and stable disease) (P = 0.012, P = 0.020,
and P = 0.025, respectively). A decrease in CA72-4 by more than 70% had a positive prediction value for pathologic
response to neoadjuvant chemotherapy according to the ROC curve (AUC: 0.764, 95% CI: 0.584 to 0.945, P = 0.020).
Conclusions: Our results suggest that high preoperative serum levels of CA72-4 and CA19-9 are associated with
higher risk of death, high pretreatment CEA levels (>50 ng/ml) may predict clinical disease progression after
neoadjuvant chemotherapy, and a decrease (>70%) of CA72-4 may predict pathologic response to
neoadjuvant chemotherapy.
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Gastric cancer is the fourth most common cancer world-
wide and the second most frequent cause of cancer death,
affecting about one million people per year [1]; surgery re-
mains the only cure for this disease. However, in a recent
study, the disease was too far advanced to receive curative
resection in more than 30% of surgical patients [2]. Des-
pite efforts for early detection, most patients with gastric
cancer in Europe and the United States continue to
present with advanced stages of the disease, therefore
the current efforts to improve survival in patients with
advanced gastric carcinoma aim to increase the rate of
complete tumor removal. Preoperative neoadjuvant
chemotherapy is an available option to achieve these
goals [3].
Neoadjuvant chemotherapy is cancer treatment in which
a drug is given to the patient prior to cancer surgery or
radical radiotherapy, and it is mostly used in cases where
surgery is planned in the future. The surgical interest in
neoadjuvant therapy for gastric cancer is driven by a long-
standing frustration with the poor outcomes achieved with
surgery alone, as well as when surgery is followed by in-
tense adjuvant chemotherapy and radiotherapy [4]. There
are several studies which indicate that neoadjuvant chemo-
therapy could increase the rate of complete tumor resec-
tions, combat systemic metastasis, and prolong survival
with tolerable and manageable toxicity, without increasing
the mortality or morbidity of surgery in gastric cancer
patients [3,5,6].
If particular patients not benefiting from preoperative
treatment, who are suggested to have a prognosis inferior
to surgery alone, could be identified, alternative therapies
may offered at an early stage [7]. Response markers are
needed to monitor treatment, and to improve quality
of life of non-responders, reduce time until surgery in
non-responders, and reduce costs [8].
Recently, tumor markers CEA, CA19-9, CA72-4, and
CA125 are widely used in gastric cancer patients, although
reports have shown the value of tumor markers as prog-
nostic factors, clinical studies evaluating the roles of
tumor markers in monitoring of chemotherapeutic effi-
cacy are limited [9], especially in neoadjuvant chemo-
therapy. In this study, we analyzed the relationship
between tumor markers CEA, CA19-9, CA72-4, and
CA125 and the response to neoadjuvant chemotherapy
in patients with gastric cancer. The aim of the study was
to determine the clinical value of tumor markers in moni-
toring the response to neoadjuvant chemotherapy and in
predicting the prognosis of gastric cancer patients.
Methods
The research was funded by Beijing Municipal Adminis-
tration of Hospitals Clinical Medicne Development of
Special Funding Support,code:XMLX201309,which wasapproved by the ethics committee on human research of
the Beijing Shijitan Hospital in accordance with the
Declaration of Helsinki.
Patients
The medical records of 184 patients who underwent neo-
adjuvant chemotherapy between 2009 and 2013 at Beijing
Shijitan hospital, Capital Medical University, were retro-
spectively reviewed. All patients had histologically con-
firmed gastric cancer and received surgical treatment after
neoadjuvant chemotherapy; patients were excluded from
the study if they demonstrated other organs insufficien-
cies, if they had experienced an acute event within the last
threemonths (cerebral, coronary, and so forth), acute in-
fection, or major trauma. The clinicopathologic features
of these patients including age, sex, and differentiation,
tumor location, depth of wall invasion, lymph node
metastasis, and vascular invasion, pTNM(Pathologic
Tumor-Node-Metastasis) stage and responses to neo-
adjuvant chemotherapy were reviewed. pTNM stages
were according to histological examination of a post-
operation, and were assigned in accordance with the
criteria established by American Joint Committee on
Cancer in 2010 [10-12]. The mean follow-up time (+/− SD)
for the entire patient population was 31.1 +/−23.2 months
(median: 24.6 months).
Neoadjuvant chemotherapy
The decision to treat patients with neoadjuvant chemo-
therapy and the neoadjuvant regimen administered was
determined by multidisciplinary tumor board discussions,
tumor histology and stage, patient ability to tolerate ther-
apy, and in accordance with National Comprehensive
Cancer Network (NCCN) guidelines.
All 184 patients received neoadjuvant chemotherapy;
5-Fu, and Leucovorin, and Oxaliplatin (FOLFOX) regimen.
The median number of cycles administered was three
(range: one to ninecycles). In all cases, surgery was per-
formed after neoadjuvant chemotherapy.
Evaluation of clinical and pathologic response
In this study, both clinical and pathologic responses are
used to evaluate the response to neoadjuvant chemother-
apy. Clinical responses to neoadjuvant chemotherapy were
determined by RECIST 1.1 response evaluation criteria in
solid tumors version 1.1 [13], and according to radio-
logical examination, including ultrasonography, computed
tomographic scan, upper gastrointestinal endoscopic as-
sessment, and upper gastrointestinal tract radiography.
Pathologic responses to neoadjuvant chemotherapy were
determined by the criteria defined by the MD Anderson
center [14-16], and according to the histological examin-
ation of post-operation, board-certified pathologists who
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specimens.
Serum assays for CEA, CA19-9, CA72-4, and CA125
Serum samples for CEA, CA19-9, CA72-4, and CA125
levels were measured at baseline and after neoadjuvant
chemotherapy respectively. Serum levels of CEA, CA19-9,
and CA72-4 were assayed with electrochemiluminescence
(ECL) method (E170, Roche Diagnostics, Rotkreuz,
Switzerland), and CA125 was measured with enzyme-
linked immunosorbent assay (ELISA, CA125-ELISA-Kit,
CanAg, Gothenburg,Sweden).
The cut-off levels were 5.0 ng/ml, 37.0 U/ml, 6.7 U/ml,
and 20.0 U/ml for CEA, CA19-9, CA72-4, and CA125, as
recommended by the manufacturer. A result was consid-
ered positive when the marker serum level was higher
than the cut-off value. Positive combined detection for
four tumor markers was defined as one or more tumor
markers above the cut-off levels.
Statistical analysis
Analyses were performed using SPSS 16.0 for Windows
(SPSS Inc., Chicago,United States). Chi-square analysis
was applied to determine the association between tumor
markers and clinicopathologic features. Survival rates
were defined in univariate analysis according to the
Kaplan-Meier method, and log-rank test was used to as-
sess statistical differences. The independent prognostic
values of each tumor marker and clinicopathologic as-
pects which significantly affect survival were assessed by
Cox multivariate analysis. T-test was applied to determine
the differences between mean levels of tumor markers be-
fore and after neoadjuvant chemotherapy. Correlations
were assessed using the Spearman rank order correlations.
Receiver-operating characteristics (ROC) curve was used
to evaluate the ability of tumor markers to predict the
response to neoadjuvant chemotherapy. Differences
were considered statistically significant when the P value
was <0.05.
Results
The diagnosis and prognosis value of pretreatment levels
of four tumor markers
The pretreatment levels of CEA, CA19-9, CA72-4, and
CA125 were above the cut-off levels in 37.9, 28.7, 36.4,
and 26.4% of cases, respectively. A total of 108 patients
showed positivity for one or more tumor markers (overall
sensitivity: 63.9%).
Table 1 shows the correlation between pretreatment
status of tumor markers and different clinicopathological
parameters. CEA was more frequently positive in the pa-
tients with lymph node involvement, well differentiation,
and cardiac carcinoma (P = 0.005, P = 0.001, and P = 0.049,
respectively), CA72-4 was more frequently positive in thepatients with advanced tumor stage and vascular invasion
(P = 0.007 and P = 0.006, respectively), and positive levels
of combined detection were related to deeper tumor inva-
sion, lymph node metastasis, and advanced tumor stage
(P = 0.041, P = 0.014, and P = 0.040, respectively).
Survival curves of patients according to pretreatment
levels of four tumor markers are shown in Figure 1. Sig-
nificant differences in survival rates were observed for
CA19-9, CA72-4 (log-rank test: P = 0.000 and P = 0.002,
respectively), a worse prognosis was observed in positive
cases. According to the survival curve for CEA and CA125,
positive cases also showed poor prognosis, but the differ-
ence did not reached statistical significance (P = 0.085 and
P = 0.409, respectively).
Furthermore, to evaluate the potential of four tumor
markers as independent predictors for overall survival of
gastric cancer, univariate and multivariate analyses were
performed (Table 2). Univariate Cox regression analysis
was used to identify the factors which were significantly
associated with overall survival. Selected these factors
into multivariate Cox regression analysis, CA19-9, CA72-4,
and pTNM stage were found as independent predictors
(P = 0.029, P = 0.008, and P = 0.001, respectively). An in-
creased pretreatment level of CA19-9 was associated with
a 2.183-fold (95% CI: 1.085 to 4.392) higher risk of death
(P = 0.029) and an increased pretreatment level of CA72-4
was associated with a 2.500-fold (95% CI: 1.269 to 4.926)
higher risk of death (P = 0.008).
Changes of tumor markers and correlation with response
to neoadjuvant chemotherapy
All 184 patients were treated with neoadjuvant chemother-
apy and clinical response to neoadjuvant chemotherapy
was noted in 151 patients; complete and partial clinical re-
sponse (CR and PR) was achieved in 65 (43.0%), stable dis-
ease (SD) in 72 (47.7%), and progression disease (PD) in
14 (9.3%) of patients. Pathologic response to neoadjuvant
chemotherapy was noted in 117 patients; complete re-
sponse (pCR) was achieved in 12 (10.3%), partial response
(pPR) in 21 (17.9%), and nonresponse (pNR) in 84 (71.8%)
of patients. The major toxic effects were nausea, anorexia,
fatigue, anemia, thrombocytopenia, and sensory neuropathy,
the major gradethree or four adverse events include
anemia, and there were no treatment-related deaths.
The levels of four tumor markers were recorded at base-
line and after neoadjuvant chemotherapy, respectively.
The mean levels of four tumor markers decreased after
neoadjuvant chemotherapy, in particular, CEA, CA72-4,
and CA125 decreased significantly (P = 0.030, P = 0.010,
and P = 0.009, respectively) (Figure 2), and these three
tumor markers decreased more significantly in the disease
control (CR + PR + SD) group than the disease progression
(PD) group (P = 0.012, P = 0.020, and P = 0.025, respect-
ively) (Figure 3).
Table 1 Association of pre-therapy status of tumor markers with clinicopathological parameters













Male 127 47(39.8) 32(28.1) 37(35.6) 14(23.3) 78(66.1)
Female 57 17(33.3) 0.424 15(30.0) 0.801 18(38.3) 0.748 9(33.3) 0.328 30(58.8) 0.366
Age(years):
≤60 92 29(33.3) 25(29.1) 31(40.8) 9(22.0) 52(59.8)
>60 92 35(42.7) 0.210 22(28.2) 0.903 24(32.0) 0.262 14(30.4) 0.370 56(68.3) 0.249
Differentiation:
Moderately 30 18(62.1) 10(38.5) 5(20.0) 4(28.6) 21(72.4)




Cardiac carcinoma 47 22(47.8) 11(24.4) 11(29.7) 1(6.2) 32(69.6)
Other locations 114 34(31.2) 0.049 28(26.7) 0.776 39(38.6) 0.336 15(24.6) 0.207 64(58.7) 0.204
Missing value 23
Invasion depth(pathological):
T1 + T2 29 8(30.8) 5(20.8) 5(21.7) 4(28.6) 12(46.2)
T3 + T4 146 53(39.6) 0.399 39(29.8) 0.372 47(39.5) 0.106 17(25.0) 1.000 90(67.2) 0.041
Missing value 9
Lymph node metastasis (pathological):
Negative 44 8(20.0) 7(18.4) 9(25.7) 5(26.3) 19(47.5)
Positive 131 54(45.0) 0.005 37(31.6) 0.117 42(39.3) 0.147 16(25.4) 1.000 83(69.2) 0.014
Missing value 9
Vascular invasion (pathological)
Negative 101 32(35.6) 24(27.6) 21(26.2) 14(29.8) 54(60.0)
Positive 66 26(41.9) 0.426 19(30.6) 0.685 27(49.1) 0.006 7(21.9) 0.435 43(69.4) 0.238
Missing value 17
pTNM stage:
I + II 53 13(27.1) 10(21.3) 9(20.5) 7(26.9) 25(52.1)
III + IV 126 50(43.1) 0.055 36(32.1) 0.168 45(44.1) 0.007 14(24.1) 0.785 80(69.0) 0.040
Missing value 5
Clinical response:
PR + SD 137 48(36.9) 35(27.6) 40(34.5) 16(24.6) 82(63.1)
PD 14 10(71.4) 0.012 4(28.6) 1.000 4(30.8) 1.000 3(50.0) 0.389 11(78.6) 0.391
Missing value 33
Pathologicresponse:
Complete and partial response 84 7(24.1) 6(21.4) 9(32.1) 4(25.0) 14(48.3)
Noresponse 33 31(39.2) 0.145 21(26.6) 0.590 24(32.9) 0.944 12(26.1) 1.000 52(65.8) 0.097
Missing value 67
Positive of combined detection for four tumor markers was defined as one or more tumor markers were above the cut-off levels.
Sun and Zhang World Journal of Surgical Oncology 2015, 12:397 Page 4 of 12
http://www.wjso.com/content/12/1/397
Figure 1 Survival curves of patients according to CEA, CA199, CA724, and CA242 pretreatment serum positivity. A. The difference between
CEA-negative patients and CEA-positive patients was not statistically significant (P = 0.085). B. The difference between CA19-9-negative patients
and CA19-9-positive patients was statistically significant (P = 0.000). C. The difference between CA72-4-negative patients and CA72-4-positive
patients was statistically significant (P = 0.002). D. The difference between CA242-negative patients and CA242-positive patients wasnot statistically
significant (P = 0.409).
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study, and patients were excluded if baseline serum
concentration was below the upper limit of normal
(ULM).
To assess the ability of the changes of tumor markers
to predict the pathologic complete and partial response
to neoadjuvant chemotherapy, ROC curve was carried
out (Figure 4). The area under the ROC curve of
CA72-4 change values was 0.764 (95% CI: 0.584 to
0.945, P = 0.020); the optimal cutoff which simultan-
eously maximized both the sensitivity (77.8%) and
specificity (80%) of the test was decreased by 71.1%.The area under the ROC curve of CA125 change values
was 0.800 (95% CI: 0.537 to 1.063, P = 0.128); the opti-
mal cutoff which simultaneously maximized both the
sensitivity (100%) and specificity (60%) of the test was
decreased by 40.0%.
To confirm the relationship between tumor marker
decrease and pathologic response, Spearman correlation
was performed;the correlation coefficient between CA72-4
decreased and pathologic response was 0.404, and the
P value was 0.018. The correlation coefficient between
CA125 decreased and pathologic response was 0.439,
and the P value was 0.133.
Table 2 Univariate and multivariate analyses of factors associated with survival in gastric cancer patients with
neoadjuvant chemotherapy
Variable Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
CA19-9
Positive versusnegative 2.198 (1.459-3.311) 0.000 2.183 (1.085-4.392) 0.029
CA72-4
Positive versusnegative 1.887 (1.241-2.869) 0.003 2.500 (1.269-4.926) 0.008
Vascular invasion
Positive versus negative 2.401 (1.616-3.567) 0.000 1.564 (0.817-2.995) 0.177
TNM (pathological)
III + IV versusI + II 6.041 (3.295-11.074) 0.000 5.066 (1.887-13.599) 0.001
Recurrence
Positive versusnegative 1.745 (1.161-2.625) 0.007 0.755 (0.337-1.693) 0.495
Clinical response to NCT
PD versus DC 2.474 (1.274-4.802) 0.007 1.103 (0.404-3.013) 0.849
Pathologic response to NCT
pCR + pPR versus pNR 0.419 (0.218-0.805) 0.009 0.739 (0.322-1.696) 0.475
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neoadjuvant chemotherapy
According to Table 1, the positivity rate of pretreatment
CEA was higher when clinical disease progression and no
pathologic response were present (P = 0.012 and P = 0.145).
Figure 3 shows that serum levels of pretreatment CEA
were higher in patients with clinical disease progression
after neoadjuvant chemotherapy.
To evaluate whether pretreatment levels of tumor
markers can be used as marker of clinical disease progres-
sion after neoadjuvant chemotherapy, an ROC curve
was carried out (Figure 5). The area under the ROC
curve of CEA pretreatment levels was 0.694 (95% CI:
0.517 to 0.871, P = 0.017); the cutoff that maximized
both sensitivity (57.1%) and specificity (85.4%) of this
test was 50 ng/ml.
The correlation between pretreatment levels of tumor
markers and pathologic response was also analyzed in
our study. The correlation coefficient between CEA pre-
treatment levels and pathologic response was 0.199, and
the P value was 0.017.
Discussion
Gastric cancer is still a major health problem worldwide
due to its frequency, poor prognosis, and limited treat-
ment options. Despite efforts for early detection, most pa-
tients with gastric cancer continue to present with an
advanced of the disease. To improve survival in these
patients, preoperative neoadjuvant chemotherapy be-
came an available option, and several studies have certi-
fied that neoadjuvant chemotherapy could down-stage
patients, improve curative respectability, and improvesurvival rates [3,5,6,17]. Despite these advantages, some
patients still have with no response to neoadjuvant chemo-
therapy, to improve the quality of life of non-responders,
reduce time until surgery, and reduce costs, the markers
which can monitor the response to neoadjuvant chemo-
therapy are needed. Our study focuses on clinical utility of
tumor markers CEA, CA19-9, CA72-4, and CA125 in gas-
tric cancer patients with neoadjuvant chemotherapy, and
the aim of the study is to measure whether these tumor
markers might be useful in monitoring response and in
predicting the prognosis of patients.
It is well known that the serum levels of various tumor
markers such as CEA, CA19-9, CA72-4, and CA125 are
elevated in patients with gastric cancer; however, there
are still controversies in the clinical use of these tumor
markers. The pretreatment positivity rates of tumor
markers are different in previous studies., CEA positivity
is normally reported at between 15.8 and 57.6%, CA19-9
at between 23.1 and 50%, and CA72-4 at between 18.6
and 58% [14,18-22], and results of our study on the per-
centage of marker positivity are within these ranges (CEA:
37.7%; CA19-9: 23.1%; CA72-4: 42.1%; and CA125:
23.2%). As previously reported [19,20,22,23], we also dem-
onstrated that the combined evaluation of the markers in
the serum showed a significant increase in the diagnostic
sensitivity documented by the percentage of cases where
the level of at least one marker was higher than its cut-off
value.
To find out the correlation between pretreatment sta-
tus of tumor markers and different clinicopathologic
parameters, we performed a chi-square test, and found
that CEA positivity was associated with lymph node
Figure 2 Mean levels of four tumor markers before and after neoadjuvant chemotherapy. A. Mean level of CEA was decreased
significantly after neoadjuvant chemotherapy (P = 0.030). B. Mean level of CA19-9 was decreased after neoadjuvant chemotherapy, the difference
was not statistically significant (P = 0.251). C. Mean level of CA72-4 was decreased significantly after neoadjuvant chemotherapy (P = 0.010).
D. Mean level of CA242 was decreased significantly after neoadjuvant chemotherapy (P = 0.009).
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[22]. In the literature, CA72-4 appeared to be the most
sensitive and specific marker in gastric cancer patients,
and its positivity was associated with advanced tumor
stage, lymph node metastasis, and distant metastasis
[18,19,21,24-27]. Our results confirm that it was associ-
ated with advanced tumor stage and vascular invasion.
In our study, we also found that the positivity of com-
bined detection of four tumor markers was related to
deeper tumor invasion, lymph node metastasis, and ad-
vance tumor stage. Through these results, we confirmed
that the pretreatment levels of tumor markers such asCEA and CA72-4 can predict the biological behavior of
gastric cancer, to some extent.
According to univariate and multivariate analyses, we
found that patients with pretreatment positive values for
tumor markers showed worse prognosis. Survival curves
(Kaplan-Meier curves) according to pretreatment levels of
CA19-9 and CA72-4 showed significant differences be-
tween positive and negative patients, and the two markers
were also confirmed to be independent prognostic factors
in multivariate analysis; our experience was consistent with
previous reports [18-22,28,29]. Cox proportional hazards
regression analysis indicated that patients with elevated
Figure 3 Mean levels of four tumor markers before and after neoadjuvant chemotherapy in disease control (CR + PR + SD) and PD
(disease progression) group respectively. A. C. D shows CEA, CA724, and CA125 decreased more significantly in the disease control (CR + PR + SD)
group than the disease progression (PD) group (P = 0.012, P = 0.020, and P = 0.025, respectively). B. show the decreased levels of CA199
was not statistically significant (P values was 0.849).
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fold higher risk of death than patients with low levels,
respectively. The reason preoperative levels of tumor
markers influence long-term survival is not clear; a number
of biological factors are probably involved [18,21,22].
Previous studies have confirmed that tumor markers
can be predictors of the response to chemotherapy in
patients with pancreatic cancer, breast cancer, epithelial
ovarian cancer, and colorectal cancer [30,34]; however,
clinical studies evaluating the roles of tumor markers in
the monitoring of chemotherapeutic efficacy in patients
with gastric cancer are limited [9]. In the present study,
we pay attention to the utility of tumor markers in mon-
itoring the response to neoadjuvant chemotherapy in
patients with gastric cancer. We found that mean levels
of tumor markers were decreased after neoadjuvant che-
motherapy, especially in the disease control group, which
included patients with complete response (CR), partial re-
sponse (PR), and stable disease (SD); mean levels decreasedmore significantly than disease progression group. The de-
creases in CEA, CA72-4, and CA125 levels achieved statis-
tical significance; we saw the same tendency in CA19-9
levels but the difference did not achieve statistical
significance. To explain this phenomenon, we reviewed
the medical records and found that pretreatment CA19-9
levels in a small number of patients were extremely
elevated; all these patients appeared to be in the disease
control after neoadjuvant chemotherapy group, and this
may be the reason why the decrease of CA19-9 levels
did not achieve statistical significance.
Based on the result that tumor markers decreased
more significantly in patients with disease control, we
did an ROC curve to assess the ability of changes in
tumor markers to predict response to neoadjuvant
chemotherapy. We found that the decrease of CA72-4
after neoadjuvant chemotherapy could predict patho-
logic response, and the cutoff value decreased by 71.1%.
This means that if CA72-4 levels decrease by more than
Figure 4 ROC curves for the decrease of the four tumor markers to predict the disease control after neoadjuvant chemotherapy. A, B.
shows the decrease of CEA, CA199 was not statistically significant (P values were 0.785, and 0.540, respectively). C. The area under the ROC curve
of CA72-4 change values was 0.764 (95% CI: 0.584 to 0.945, P = 0.020); the optimal cutoff which simultaneously maximized both the sensitivity
(77.8%) and specificity (80%) of the test was decreased by 71.1%. D. The area under the ROC curve of CA125 change values was 0.800 (95% CI:
0.537 to 1.063, P = 0.128); the optimal cutoff which simultaneously maximized both the sensitivity (100%) and specificity (60%) of the test was
decreased by 40.0%.
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pPR. We also found that the area under the ROC curve
of CA24-2 change values was 0.800; the cutoff value was
decreased 40.0% but the difference did not achieve stat-
istical significance. Our inability to demonstrate that the
decrease of CA125 can also predict pathologic responseto neoadjuvant chemotherapy may be due to the relatively
small number of patients analyzed.
Using chi-square analysis, we found positive pretreat-
ment levels of CEA were associated with clinical disease
progression after neoadjuvant chemotherapy; and using
t-test, we found CEA levels in the disease progression
Figure 5 ROC curves for pretreatment levels of tumor markers to predict the disease progression after neoadjuvant chemotherapy. A.
The area under the ROC curve of CEA pretreatment levels was 0.694 (95% CI: 0.517 to 0.871, P = 0.017); the cutoff that maximized both sensitivity
(57.1%) and specificity (85.4%) of this test was 50 ng/ml. The correlation coefficient between CEA pretreatment levels and pathologic response
was 0.199, and the P value was 0.017. B.C.D show the pretreatment levels of CA72-4, CA199, and CA125 were not statistically significant (P values
were 0.381, 0.719, and 0.967 respectively).
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Therefore, we speculated that high pretreatment level of
CEA may predict clinical disease progression. In order
to confirm this, we carried out an ROC curve and found
pretreatment level of CEA can predict clinical disease
progression after neoadjuvant chemotherapy; the cutoff
value was 50 ng/ml. Therefore, if the pretreatment levelof a patient is more than 50 ng/ml, he has a higher of
being a non-responder.
It is well known that elevated marker levels decrease
after curative resection of the tumor, only to elevate
again on recurrence [9,35,36]. Therefore some researchers
have postulated that the change in these tumor markers
would reflect the relative tumor burden in individual
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had been elevated prior to chemotherapy [9]. We are
agree with this speculation as tumor markers can be
produced directly by the tumor or non-tumor cells as a
response to the presence of a tumor, so a high level of
tumor marker may mean a large tumor burden. This
may be the reason why high pretreatment levels of
tumor markers can predict poor prognosis, and why
high CEA levels can predict poor response to neo-
adjuvant chemotherapy. Tumor burden will be reduced
by effective treatment such as neoadjuvant chemo-
therapy, and tumor shrinkage always accompanies a
drop in marker levels, therefore we can see a decrease
in tumor markers after neoadjuvant chemotherapy,
especially in patients with disease control.
The limitations of our study include that the number
of patients analyzed here is very small and missing values
still exist. Due to the low sensitivity and specificity, these
tumor markers cannot replace other detection methods,
such as pathological examination and imaging studies.Conclusions
In conclusion, the measurement of tumor markers might
be useful in the monitoring of response, and in the predic-
tion of prognosis in patients treated with neoadjuvant
chemotherapy. This is especially true in the cases in which
disease is difficult to evaluate by imaging studies. Further
studies are required to confirm these findings.
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